In addition, although it is necessary to further study whether USP7 regulates the ERK1/2 signaling pathway via the same mechanism in other cancer cells, inhibition of the ERK1/2 signaling pathway through USP7 could be a good target for new cancer therapeutics along with p53/MDM2 targeting. This evidence concerns the gene TP53 and cancer.